<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/71298">
      <dc:title>Furosemide/Non-Steroidal Anti-Inflammatory Drug–Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation</dc:title>
      <dc:creator>Acebedo Martínez, Francisco Javier</dc:creator>
      <dc:creator>Alarcón-Payer, Carolina</dc:creator>
      <dc:creator>Rodríguez Domingo, Lucía</dc:creator>
      <dc:creator>Domínguez Martín, Alicia</dc:creator>
      <dc:creator>Gómez Morales, Jaime</dc:creator>
      <dc:creator>Choquesillo Lazarte, Duane</dc:creator>
      <dc:subject>Drug–drug cocrystal</dc:subject>
      <dc:subject>Furosemide</dc:subject>
      <dc:subject>Ethenzamide</dc:subject>
      <dc:subject>Piroxicam</dc:subject>
      <dc:subject>Mechanochemical synthesis</dc:subject>
      <dc:description>The design of drug–drug multicomponent pharmaceutical solids is one the latest drug&#xd;
development approaches in the pharmaceutical industry. Its purpose is to modulate the physicochemical properties of active pharmaceutical ingredients (APIs), most of them already existing in&#xd;
the market, achieving improved bioavailability properties, especially on oral administration drugs.&#xd;
In this work, our efforts are focused on the mechanochemical synthesis and thorough solid-state&#xd;
characterization of two drug–drug cocrystals involving furosemide and two different non-steroidal&#xd;
anti-inflammatory drugs (NSAIDs) commonly prescribed together: ethenzamide and piroxicam.&#xd;
Besides powder and single crystal X-ray diffraction, infrared spectroscopy and thermal analysis,&#xd;
stability, and solubility tests were performed on the new solid materials. The aim of this work was&#xd;
evaluating the physicochemical properties of such APIs in the new formulation, which revealed&#xd;
a solubility improvement regarding the NSAIDs but not in furosemide. Further studies need to be&#xd;
carried out to evaluate the drug–drug interaction in the novel multicomponent solids, looking for&#xd;
potential novel therapeutic alternatives.</dc:description>
      <dc:date>2021-11-05T08:04:37Z</dc:date>
      <dc:date>2021-11-05T08:04:37Z</dc:date>
      <dc:date>2021</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>Acebedo-Martínez, F.J.; Alarcón-Payer, C.; RodríguezDomingo, L.; Domínguez-Martín, A.; Gómez-Morales, J.; ChoquesilloLazarte, D. Furosemide/NonSteroidal Anti-Inflammatory Drug–Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation. Crystals 2021, 11, 1339. https://doi.org/10.3390/ cryst11111339</dc:identifier>
      <dc:identifier>http://hdl.handle.net/10481/71298</dc:identifier>
      <dc:identifier>10.3390/cryst11111339</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Atribución 3.0 España</dc:rights>
      <dc:publisher>MDPI</dc:publisher>
   </ow:Publication>
</rdf:RDF>